Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non–Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial

Bezjak, Andrea; Paulus, Rebecca; E. Gaspar, Laurie; D. Timmerman, Robert; L. Straube, William; F. Ryan, William; I. Garces, Yolanda; T. Pu, Anthony; K. Singh, Anurag; M. Videtic, Gregory; C. McGarry, Ronald; Iyengar, Puneeth; R. Pantarotto, Jason; J. Urbanic, James; Y. Sun, Alexander; E. Daly, Megan; S. Grills, Inga; Sperduto, Paul; P. Normolle, Daniel; D. Bradley, Jeffrey; Choy, Hak

doi:10.1200/jco.18.00622

Public

Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non–Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial

Shared by NobleBlocks on May 20, 2019 • 12:00 AM UTC

Authors:

Andrea Bezjak

Rebecca Paulus

Laurie E. Gaspar

Abstract

PURPOSE Patients with centrally located early-stage non–small-cell lung cancer (NSCLC) are at a higher risk of toxicity from high-dose ablative radiotherapy. NRG Oncology/RTOG 0813 was a phase I/II study designed to determine the maximum tolerated dose (MTD), efficacy, and toxicity of stereotactic b...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!